Supporting the future of mental health​ & dementias

Combining patient data* and world class AI powered NLP to accelerate real world evidence, clinical trial optimisation and molecular characterisation of disease

Clinical Trial Optimisation

Link healthcare organisations with Pharmaceutical and Biotechnology companies to help deliver their R&D Strategy, generate revenue and improve trial efficiencies

Study Feasibility

Increase speed to first patient in data-driven analysis. Model, compare, and optimise feasibility scenarios faster. Study feasibility can help identify challenges beforehand and help in taking a decision on how to work efficiently at every stage of the study.

Patient Re-Identification

Use our safe re-identification service to enrol patients and begin your clinical trial with your pre-defined cohort of patients.


Use our safe re-identification service to enrol patients and begin your clinical trial with your pre-defined cohort of patients.

Patient and Site Recruitment and Retention

Understand which sites may result in better patient recruitment and retention based upon the characteristics of the patients.

Market Impact Analysis

Build custom analytics and build customer charts and tables in the Akrivia Health platform to gain insights into drug usage patterns to understand medication usage and errors.

Post Launch Evaluation and Pharmacovigilence

The combination of the Akriva Health platform, application of the OMOP Common Data Model and our AI Scientists provide the capability to identify the quality of data and the evidence that can be generated from the clinical records thus reducing time and resource needed to collect, investigate and report on adverse events.

Market Access and Sales Tracking

The Akrivia Health platform identifies which competing drugs are being used as potentially within specific clinical scenarios, off label use and where potential compliance issues may exist. In addition, the data will be able to support Patient Access Schemes should the drug is considered to be too expensive by local government.

Early stage drug discovery

Work with the de-identified data to identify unmet medical needs and the potential causes behind these conditions leading to early stage drug discovery.

Service Evaluation and Quality Improvement audit

There is still limited opportunity to work with de-identified patient level data, that has been structured, to conduct strategic or operational reviews. Where it is available, organisations do not have the ability to extract key information due to data formats and a lack of coding standards, missing data and duplicate data.

Information Governance constraints often limit the capability to conduct analysis using a federated search. Our platform enables work to be conducted on models that are statistically valid across multiple organisations under a robust Information Governance model.

Worldwide, 1 billion people are living with mental health conditions plus a further 50 million with dementia. The global trend of ageing populations will continue to increase the numbers of those impacted either directly or indirectly. Just 6% of UK health research spending goes on mental health

Society is increasingly becoming aware, accepting and talking about mental health conditions. Private and Public funding of effective care is needing to match these changes.

The global research community is increasing the availability of effective therapeutic and non-therapeutic options through service improvements, next generation products and the safe use of existing drugs for multiple conditions. However, clinical trials remain expensive and take longer than needed.

Global clinical trials, across all therapeutic areas, are projected to cost over £150 billion per annum by 2024. On average, the launch of each drug costs an estimated £2 billion. Trial costs continue to rise due to more complex drugs, increased complexity of trial methods and larger, multi-continent trials to achieve regulatory clearance.

For Central Nervous System drugs, trial costs tend to be higher as they have a greater failure rate at a later stage especially when introducing first-in-class therapeutics with an unprecedented mode of action.

Lengthy drug approval procedures can result in drug trials of 13-15 years. However, with patents only lasting 20 years and exclusivity for 7 years, limited time exists for a pharmaceutical company to re-gain their investment.

It is estimated that reducing a development programme by 18 months can increase the value of a drug by £150 million and will provide quicker therapeutic benefits to patients.

Life Sciences

Akrivia Health enables organisations to securely work with the world’s largest and most in-depth dataset comprised of structured psychiatric data, enabling research, drug discovery and development. 

Our Approach

Over the last 5 years, the Akrivia Health team and our NHS Healthcare partners have been developing the world’s largest and richest repository of real-world data in dementia and psychiatric conditions.

Healthcare Organisations

Our network is comprised of specialist care providers of mental health and dementia services. The community shares innovation, service improvements and research outcomes through networking and training. 

Akrivia Health In numbers

0 m
De-identified patient records
Years of clinical interactions
0 bn
Clinical data
0 m
0 m

With billions of data points, our diverse real world data and real world evidence, complements the need for valued research within mental health and dementia.

Data: The Difference

We have worked with our NHS Healthcare Partners to develop the world’s largest specialist mental health and dementia clinical dataset. Over      4.6 million de-identified patient records are updated on a regular basis.

Our longitudinal dataset includes diagnosis, medications, outcomes, signs and symptoms, and care plans covering 15 years. We continue to combine additional data sets, such as the UK BioBank, to enable precision psychiatry models to be developed.

Over the last 5 years, our team has been using Natural Language Processing and AI to generate structured data out of de-identified psychiatry clinical records. The clinical notes, which comprise 70-80% of the information available, are being turned into 17 billion data points.

We believe that data in this multi-factorial disease area is only useful if its context can be understood and is made easily available.

4.6 Million+ Patients

Each with multiple health system interactions, providing tens of millions of de-identified electronic patient records and a rich, diverse dataset.